

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+1.42%
+4.00%
+1.50%
+2.86%
-1.82%
IOBT
IO Biotech
$1.02
Strengths

Earnings are forecast to grow
Chart
$1.58 (-35.44%)
$2.25 (-54.67%)
$1.51 (-32.45%)
$1.16 (-12.07%)
IOBT has Moderate Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators

Price under $5

High volatilty

IOBT overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Loss widens YoY
Rating
Rating
Momentum
Momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
IOBT Analysts opinion is negative but has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
IOBT Street view is extremely bullish and have negative views on the near-term outlook
Average key support and resistance price levels.
Login to displayWhat is IOBT current stock price?
What are IOBT stock strengths?
What risks are associated with IOBT stock?
When is IOBT next earnings report?
What is IOBT market cap and volume?
What is IOBT's current Stock IQ?
Should I buy IOBT stock right now?
Is IOBT a Strong Buy right now?
What does a 'Strong Buy' rating mean for IOBT?
What does a 'Strong Sell' rating mean for IOBT?
What factors influence IOBT's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+1.42%
+4.00%
+1.50%
+2.86%
-1.82%
IOBT
IO Biotech
Current Price
$1.02
Stock Insights
Strengths

Earnings are forecast to grow
Chart
$1.58 (-35.44%)
$2.25 (-54.67%)
$1.51 (-32.45%)
$1.16 (-12.07%)
IOBT Analysts Opinion
IOBT Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Loss widens YoY
Rating
Rating
Momentum
Momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
IOBT Analysts opinion is negative but has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
IOBT Street view is extremely bullish and have negative views on the near-term outlook
IOBT has Moderate Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators

Price under $5

High volatilty

Average key support and resistance price levels.
IOBT Latest Analysis
Piper Sandler Maintains IO Biotech (IOBT) Overweight Recommendation. Fintel reports that on October 22 2025 Piper Sandler maintained coverage of IO Biotech (NasdaqGS:IOBT) with a Overweight recommendation. Analyst Price Forecast Suggests 533.90% Upside
Thu Oct 23, 2025
IO Biotech Reveals Positive Phase 3 Results For Cylembio Plus Keytruda In Advanced Melanoma . (RTTNews) - IO Biotech (IOBT) a clinical-stage biopharmaceutical company focused on cancer vaccines Monday reported positive phase 3 results for Cylembio in combination with Merck & Co Inc.s (MRK) anti-PD-1 therapy KEYTRUDA (pembrolizumab) for the first-line treatment of pati
Mon Oct 20, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
IOBT Stock trends
IOBT Stock performance
IOBT Stock analysis
IOBT investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.